October 20th, 2016
•We describe a high-throughput, multiplex, and targeted proteomic cerebrospinal fluid (CSF) assay developed with potential for clinical translation. The test can quantitate potential markers and risk factors for neurodegeneration, such as the apolipoprotein E variants (E2, E3 and E4), and measure their allelic expression.
Tags
Videos relacionados
Mouse Eye Enucleation for Remote High-throughput Phenotyping
Biomarkers in an Animal Model for Revealing Neural, Hematologic, and Behavioral Correlates of PTSD
High Content Screening in Neurodegenerative Diseases
High Throughput Sequential ELISA for Validation of Biomarkers of Acute Graft-Versus-Host Disease
High-throughput Flow Cytometry Cell-based Assay to Detect Antibodies to N-Methyl-D-aspartate Receptor or Dopamine-2 Receptor in Human Serum
High Throughput Characterization of Adult Stem Cells Engineered for Delivery of Therapeutic Factors for Neuroprotective Strategies
An Optimized Hemagglutination Inhibition (HI) Assay to Quantify Influenza-specific Antibody Titers
Induction of Atherosclerotic Plaques Through Activation of Mineralocorticoid Receptors in Apolipoprotein E-deficient Mice
High-throughput Nitrobenzoxadiazole-labeled Cholesterol Efflux Assay
An Improved and High Throughput Respiratory Syncytial Virus (RSV) Micro-neutralization Assay
ACERCA DE JoVE
Copyright © 2024 MyJoVE Corporation. Todos los derechos reservados